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Abstract
Background:  There are controversial results on the efficacy of the abandoned, intrathecal
predominant methylprednisolone application in multiple sclerosis (MS) in contrast to the proven
effectiveness in intractable postherpetic neuralgia.
Methods: We performed an analysis of the efficacy of the application of 40 mg of the sustained
release steroid triamcinolone acetonide (TCA). We intrathecally injected in sterile saline dissolved
TCA six times within three weeks on a regular basis every third day in 161 hospitalized primary
and predominant secondary progressive MS patients with spinal symptoms. The MS patients did not
experience an acute onset of exacerbation or recent distinct increased progression of symptoms.
We simultaneously scored the MS patients with the EDSS and the Barthel index, estimated the
walking distance and measured somatosensory evoked potentials. Additionally the MS patients
received a standardized rehabilitation treatment.
Results:  EDSS score and Barthel index improved, walking distance increased, latencies of
somatosensory evoked potentials of the median and tibial nerves shortened in all MS patients with
serial evaluation (p < 0.0001 for all variables). Side effects were rare, five patients stopped TCA
application due to onset of a post lumbar puncture syndrome.
Conclusions: Repeated intrathecal TCA application improves spinal symptoms, walking distance
and SSEP latencies in progressive MS patients in this uncontrolled study. Future trials should
evaluate the long-term benefit of this invasive treatment.
Background
There are controversial results on the efficacy of the now-
adays still abandoned, intrathecal steroid application pre-
dominantly due to a missing detailed evaluation of
patients' characteristics, careful monitoring and standard-
ized outcome measurements in multiple sclerosis (MS)
[1]. Initially, case reports of intrathecal methylpredniso-
lon and ACTH administration described beneficial effects
in MS patients, but the following studies showed disap-
pointing results in particular in comparison to systemic
steroid application [1]. Earlier intrathecal treatment trials
in MS patients suffered from small sample sizes, low
number of injections, low steroid dosages, short half life
of the administered steroid and an increasing number of
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reports on side-effects, i.e. adhesive arachnoiditis and var-
ious forms of meninigitis probably due to neurotoxic sol-
vents and bacteriostatic additives [4]. Moreover a retarded
release steroid preparation was not available for many
years [1,5]. Then administration of triamcinolone aceto-
nide crystal suspensions (TCA), dissolved at bedside in
sterile saline, was introduced in the intrathecal steroid
treatment of MS. However, studies again lacked of
detailed evaluation and clinical characterization of MS
patients, small sample sizes and a low number of intrath-
ecal application of this retarded release steroid compound
[1,4,5].
Accordingly, there was no convincing superiority over the
efficacy of the systemic steroid treatment. Some enrolled
MS patients experienced a recent deterioration of symp-
toms due to prior acute relapses and/or ongoing chronic
progression. Moreover study participants were not classi-
fied according to the various subtypes of MS progression
[5,6]. However in general, a comparison of both methods
of steroid application is at least doubtful from the phar-
macokinetic point of view. The resulting steroid efficacy in
the central nervous system enormously differs in favor for
the intraspinal application due to the achieved cerebrospi-
nal fluid steroid level, marked longer half life, i.e. with
detection of TCA even four months after the last adminis-
tration, and missing impact on the endogenous periph-
eral cortisol secretion with no appearance of side effects of
systemic high dosage steroid application [4,6]. In recent
years, a certain revival of intrathecal methylprednisolon
administration took place in the treatment of intractable
postherpetic neuralgia and MS with spinal symptoms,
both of which turned out to be very effective, but were
controversially discussed regarding the safety issues [2,3].
The MS study demonstrated, that six repeat intrathecal
TCA injections within three weeks reduced the EDSS score
in 31 of 36 progressive MS patients with predominant spi-
nal symptoms. 20 of them entered a follow-up period of
13.1 ± 6.22, 3 – 23 [mean ± SD, range] months with 6.35
± 3.91, 2 – 15 TCA injections. They received one TCA
application on a regular basis in an individually differing
frequency every six to twelve weeks. These patients
remained stable [3]. Nevertheless, there is a need for fur-
ther results on the usefulness of this treatment. The opti-
mum design would be a placebo-controlled arm, but
repeat performance of intrathecal saline (placebo) admin-
istration under double-blind conditions with the patients'
consent and an approval of an ethical committee is not
realistic in clinical practice. Moreover they may be ethical
concerns of withholding treatment [7]. Our present study
is a way out of this dilemma of the debate on the efficacy
of TCA treatment, which is carried out in certain specific
centers in Germany for many years now [3]. We per-
formed an analysis of standardized intrathecal applica-
tion of TCA in MS patients with spinal symptoms, using
subjective rating procedures and objective measurements.
Methods
Subjects
We only enrolled clinically well characterized, consecu-
tively referred MS patients (table 1, 2) with distinct spinal
symptoms and/or MRT visualized lesions in the spinal
cord [8]. These patients did not suffer from an acute onset
of exacerbation or recent clearly increased progression of
their symptoms.
Methods
We performed scoring with both, EDSS and Barthel index
and assessed the walking distance. Then we measured
somatosensory evoked potentials (SSEP) in a standard-
ized fashion before start and at the end of the intraspinal
TCA treatment within a prospective study design [9]. A
technician performed SSEP recordings and measured the
walking distance. We blinded the EDSS raters. Retrospec-
tively, we compiled information on patients from their
hospital records, i.e. date of birth, sex, duration of disease
after diagnosis of MS, dosages of oral baclofen (lioresal®),
tolperison (mydocalm®), tizanidin (sirdalud®) on the first
and last day of the hospital stay, length of hospitalization
in days (tables 1 &2). The patients additionally received a
standardized rehabilitation treatment, which included
physiotherapy, massage and optional swimming with the
patients' consent [12,13]. Only data with successfully per-
formed serial evaluation of patients were compared for
each variable. We performed lumbar puncture with an
"atraumatic" Sprotte needle [10,11]. Each patient received
six intrathecal applications of 40 mg TCA followed by a
mandatory stay in bed for at least six hours. This should
reduce incidence of lumbar puncture syndrome and
hypothetically support the diffusion of TCA in the CSF
and the spinal cord [14,15]. A preexisting immune system
modulating drug therapy remained stable. We closely
monitored for typical concomitant with systemic steroid
application appearing side effects, i.e. increase of body
weight etc., all of which did not significantly change (data
not shown) [16]. No slight or severe side effects occurred,
but we did not include five patients into our evaluation
due to onset of post lumbar puncture syndrome with
Table 1: Patients' characteristics.
Age 50.10 ± 10.30, 21 – 78 years
Duration of MS 14.32 ± 7.63, 2 – 40 years
Sex 119 men, 42 women
MS types chronic progressive: n = 35
secondary progressive: n = 122
relapsing-remitting: n = 4
Length of hospital stay 28.41 ± 5.97; 21 – 60 daysBMC Neurology 2004, 4:18 http://www.biomedcentral.com/1471-2377/4/18
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headache and nausea, which caused a stop of further
intrathecal TCA applications. These patients withdraw
their consent. We only considered SSEP data of patients
with serial measurements, which we performed on the
same day of the EDSS rating.
Ethics
Each participant gave written informed consent for the
TCA treatment, which was approved by the local ethical
committee. The consent form included a detailed descrip-
tion of all putative risks of lumbar puncture and intrathe-
cal TCA application.
Statistics
Data showed a normal distribution according to the Kol-
mogorow-Smirnow test. As a result, we only performed
parametric tests. We used ANCOVA with repeated meas-
ures design including MS duration, MS types, change of
dosages of concomitant drugs against spasticity, length of
hospital stay, sex and age as covariates. We computed
SSEP results by adding both sides in order to reduce
amount of calculations for comparisons. Then we calcu-
lated the differences of latencies between both timepoints
of recordings according to the formula [Initial - End =
Diff] for correlation analysis. We employed linear regres-
sion for correlation analysis. Level of significance of p-val-
ues were adjusted to 0.05 divided by the number of
performed comparisons respectively correlations.
Results
Comparisons
EDSS score (n [number of subjects with serial evaluation]
= 161) and Barthel index (n = 68) improved and walking
distance (n = 161) increased (table 3). SSEP latencies of
tibial (n = 136) and median (n = 108) nerves reduced
(table 3). P-values of all performed comparisons were
below 0.0001. No significant effects of covariates
appeared.
Correlation analysis
There were no significant relations between computed
changes of EDSS scores, walking distances and SSEP
results (results not shown). Diff P2 correlated with Diff P3
(R [correlation coefficient] = 0.71), Diff P2 with Diff N2
(R = 0.90), Diff P3 with Diff N2 (R = 0.74) of SSEP laten-
cies of the tibial nerves. There were relations between Diff
N2 and Diff P2 (R = 0.85) of SSEP latencies of the median
nerves. P-values of these correlations were below 0.0001.
Moreover Diff P2 of the tibial nerves correlated with Diff
N2 of the median nerves (R = 0.28, p = 0.004, n = 100).
There was a certain trend for a significant correlation
between Diff P2 of the tibial nerve and Diff P2 of the
median nerve (R = 0.22, p = 0.03). No other significant
associations of SSEP data appeared (results not shown).
Discussion
Our results demonstrate and confirm the efficacy of
repeated intraspinal TCA application in MS patients with
spinal symptoms, which improved according to the EDSS
outcomes and the results of assessed walking distance and
determined SSEP latencies [3]. We intrathecally injected
TCA six times within three weeks, whereas earlier trials
weekly performed one application up to three times at the
most [4]. The distinct reduction of SSEP peak latencies
and the significant relations between their computed dif-
ferences confirm the clinical outcomes and underline the
efficacy of intraspinal TCA treatment in MS patients with
spinal symptoms in general. We hypothesize, that these
neurophysiological results indicate a certain remyelinat-
ing and/or restorative potential of intraspinal TCA
application with an at least transient shift from chronic
inflammation to remyelination [17,18]. Our results sup-
port the crucially discussed view, that serial SSEP studies
in MS may monitor the effect of treatment to a certain
extent under standardized conditions [9,19,20]. Our anal-
ysis also shows that primary and secondary progressive
even advanced MS patients with spinal symptoms pre-
dominantly improve from this kind of intrathecal steroid
therapy. We assume, that we achieve persistent high ster-
oid concentrations at lesions of the spinal cord, since TCA
must not pass the blood brain barrier [6]. However previ-
ous comparisons of the clinical efficacy of intrathecal TCA
application with the intravenous administration of meth-
ylprednisolone showed no superiority of one method
over the other [5,6,19]. But these studies did not exclude
relapsing remitting patients or participants with a previ-
Table 2: Treatment against spasticity.
Before TCA After TCA
Baclofen 7.56 ± 16.06; 0 – 80 mg, n = 117 without baclofen 6.44 ± 15.51; 0 – 80 mg, n = 125 without baclofen
Tolperison 1.19 ± 8.20; 0 – 75 mg, n = 154 without tolperison 1.34 ± 7.41; 0 – 50 mg, n = 152 without tolperison
Tizanidin 1.94 ± 5.29; 0 – 32 mg, n = 132 without tizanidin 3.38 ± 6.64; 0 – 32 mg, n = 110 without tizanidin
All data are given as mean ± standard deviation; minimum – maximum; n = number of patients; TCA = standardized intrathecal triamcinolon 
acetonide application according to the methods section.BMC Neurology 2004, 4:18 http://www.biomedcentral.com/1471-2377/4/18
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ous acute relapse. They did not focus on spinal symptoms.
Their application rate of TCA was distinct lower compared
with the one of our present and a previous trial [3].
However our present study outcomes do not allow any
conclusions on the duration of the achieved benefit and
the impact of TCA treatment on progression of MS [3].
Therefore there is an urgent need for further confirmatory
trials, which additionally address all these issues. A strat-
egy would be to choose one arm with active treatment and
one arm with just follow-up without active treatment with
blind assessment by an evaluating physician. However we
stress concerning long-term steroid therapy and progres-
sion of MS, that there are positive outcomes of trials with
intravenous methylprednisolone administration in vari-
ous application rates and dosages on long term disease
progression and/or on brain atrophy in secondary-pro-
gressive -, respectively relapsing-remitting MS patients
[16,21]. In contrast to studies on intravenous oral steroid
treatment, we did not observe the typical side effects of
systemic high dosage steroid administration, i.e. edema.
This may support previous findings by circumstantial evi-
dence, which report no decrease of endogenous cortisol
secretion following intrathecal TCA administration [4].
We cannot exclude a certain impact of physiotherapy, the
standardized rehabilitation treatment and an beneficial
effect of hospitalization in general with its resulting con-
comitant positive influence on activities of daily living
[12,13]. However, we found no significant impact of the
corresponding covariate length of the hospital stay in our
statistical analysis. We assume, that our results do not
reflect an improved drug therapy against spasticity, since
no significant impact of the covariate computed changes
of medication appeared. Nevertheless we cannot exclude
a certain effect of the steroid on spasticity. However most
participants did not take any drug against spasticity. Onset
of side effects of lumbar puncture itself were negligible,
since we used an atraumatic needle [11].
Conclusions
Our data demonstrate the efficacy and safety of repeated
intrathecal TCA application in MS patients with predomi-
nant spinal symptoms, which markedly improved. Some
MS patients experienced post lumbar puncture syndrome
with a frequency within the normal range [11], but typical
side effects of systemic high dosage steroid administration
did not appear.
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